MA39294A1 - Polythérapie contre le cancer - Google Patents
Polythérapie contre le cancerInfo
- Publication number
- MA39294A1 MA39294A1 MA39294A MA39294A MA39294A1 MA 39294 A1 MA39294 A1 MA 39294A1 MA 39294 A MA39294 A MA 39294A MA 39294 A MA39294 A MA 39294A MA 39294 A1 MA39294 A1 MA 39294A1
- Authority
- MA
- Morocco
- Prior art keywords
- combytherapy
- against cancer
- fluoro
- benzoimidazol
- piperazin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
La présente invention concerne la préparation de médicaments destinés à être utilisés dans le traitement et des méthodes de traitement du cancer du poumon non à petites cellules chez un patient comprenant: de la [5-(4-éthyl-pipérazin-1-ylméthyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-méthyl-3h-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine ou un sel pharmaceutiquement acceptable de celle-ci, en combinaison, tel qu'également décrit dans l'invention, avec un anticorps anti-vegfr2, de préférence, le ramucirumab.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461944811P | 2014-02-26 | 2014-02-26 | |
PCT/US2015/016529 WO2015130540A1 (fr) | 2014-02-26 | 2015-02-19 | Polythérapie contre le cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
MA39294A1 true MA39294A1 (fr) | 2018-06-29 |
MA39294B1 MA39294B1 (fr) | 2018-12-31 |
Family
ID=52630493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39294A MA39294B1 (fr) | 2014-02-26 | 2015-02-19 | Polythérapie contre le cancer |
Country Status (18)
Country | Link |
---|---|
US (1) | US10238656B2 (fr) |
EP (1) | EP3110444B1 (fr) |
JP (1) | JP5948525B1 (fr) |
KR (1) | KR20160111001A (fr) |
CN (1) | CN106029097A (fr) |
AP (1) | AP2016009402A0 (fr) |
AU (1) | AU2015223359B2 (fr) |
BR (1) | BR112016016880A2 (fr) |
CA (1) | CA2936558A1 (fr) |
EA (1) | EA201691385A1 (fr) |
ES (1) | ES2659424T3 (fr) |
IL (1) | IL246761A0 (fr) |
MA (1) | MA39294B1 (fr) |
MX (1) | MX2016011045A (fr) |
MY (1) | MY176219A (fr) |
SG (1) | SG11201606958YA (fr) |
TW (1) | TWI558399B (fr) |
WO (1) | WO2015130540A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201625304A (zh) * | 2014-10-24 | 2016-07-16 | 美國禮來大藥廠 | 泌尿上皮癌之療法 |
CN108883182A (zh) * | 2016-04-15 | 2018-11-23 | 伊莱利利公司 | 用于治疗套细胞淋巴瘤的雷莫芦单抗和abemaciclib的组合治疗 |
EP3502103B1 (fr) * | 2016-09-09 | 2022-04-06 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Forme cristalline, type de sel d'un dérivé de 2-hydro-pyrazole substitué et son procédé de préparation |
US20200062836A1 (en) * | 2016-11-16 | 2020-02-27 | Eli Lilly And Company | THERAPY FOR METATASTIC COLORECTAL CANCER USING ANTI-VEGFR-2 and ANTI-VEGF-D ANTIBODIES |
CN112119073A (zh) | 2018-04-05 | 2020-12-22 | 庄信万丰股份有限公司 | 阿贝西尼的固态形式、其用途和制备 |
JP2021517583A (ja) * | 2018-04-06 | 2021-07-26 | イーライ リリー アンド カンパニー | 小児患者における癌の治療のためのラムシルマブ |
WO2020239051A1 (fr) * | 2019-05-30 | 2020-12-03 | 江苏恒瑞医药股份有限公司 | Utilisations d'un inhibiteur de cdk4/6 conjointement avec un inhibiteur de vegfr dans la préparation d'un médicament pour le traitement d'une tumeur |
WO2021030843A1 (fr) | 2019-08-13 | 2021-02-18 | Johnson Matthey Public Limited Company | Formes solides d'abemaciclib, leur utilisation et leur préparation |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030108545A1 (en) * | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
EP2275540B1 (fr) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Procédé de contrôle de l'activité de molécule fonctionnelle immunologique |
EP1229125A4 (fr) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | Procede de production d'un polypeptide |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
ATE475431T1 (de) * | 2002-03-04 | 2010-08-15 | Imclone Llc | Kdr-spezifische humane antikörper und deren anwendung |
US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
DE60332957D1 (de) | 2002-12-16 | 2010-07-22 | Genentech Inc | Immunoglobulinvarianten und deren verwendungen |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
JO2885B1 (en) * | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
UY33226A (es) * | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
-
2015
- 2015-02-13 TW TW104105148A patent/TWI558399B/zh not_active IP Right Cessation
- 2015-02-19 US US15/115,995 patent/US10238656B2/en not_active Expired - Fee Related
- 2015-02-19 EA EA201691385A patent/EA201691385A1/ru unknown
- 2015-02-19 MA MA39294A patent/MA39294B1/fr unknown
- 2015-02-19 EP EP15708638.0A patent/EP3110444B1/fr active Active
- 2015-02-19 CA CA2936558A patent/CA2936558A1/fr not_active Abandoned
- 2015-02-19 AP AP2016009402A patent/AP2016009402A0/en unknown
- 2015-02-19 JP JP2016505628A patent/JP5948525B1/ja not_active Expired - Fee Related
- 2015-02-19 MX MX2016011045A patent/MX2016011045A/es unknown
- 2015-02-19 KR KR1020167022971A patent/KR20160111001A/ko active Search and Examination
- 2015-02-19 CN CN201580010432.3A patent/CN106029097A/zh active Pending
- 2015-02-19 AU AU2015223359A patent/AU2015223359B2/en not_active Expired - Fee Related
- 2015-02-19 ES ES15708638.0T patent/ES2659424T3/es active Active
- 2015-02-19 WO PCT/US2015/016529 patent/WO2015130540A1/fr active Application Filing
- 2015-02-19 BR BR112016016880A patent/BR112016016880A2/pt not_active Application Discontinuation
- 2015-02-19 MY MYPI2016703120A patent/MY176219A/en unknown
- 2015-02-19 SG SG11201606958YA patent/SG11201606958YA/en unknown
-
2016
- 2016-07-13 IL IL246761A patent/IL246761A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG11201606958YA (en) | 2016-09-29 |
TWI558399B (zh) | 2016-11-21 |
AP2016009402A0 (en) | 2016-08-31 |
TW201542209A (zh) | 2015-11-16 |
KR20160111001A (ko) | 2016-09-23 |
MY176219A (en) | 2020-07-24 |
US20170173013A1 (en) | 2017-06-22 |
EP3110444A1 (fr) | 2017-01-04 |
ES2659424T3 (es) | 2018-03-15 |
JP2016521262A (ja) | 2016-07-21 |
AU2015223359A1 (en) | 2016-08-11 |
JP5948525B1 (ja) | 2016-07-06 |
US10238656B2 (en) | 2019-03-26 |
IL246761A0 (en) | 2016-08-31 |
BR112016016880A2 (pt) | 2017-10-03 |
CA2936558A1 (fr) | 2015-09-03 |
MX2016011045A (es) | 2016-10-28 |
AU2015223359B2 (en) | 2017-06-01 |
EA201691385A1 (ru) | 2016-12-30 |
WO2015130540A1 (fr) | 2015-09-03 |
MA39294B1 (fr) | 2018-12-31 |
CN106029097A (zh) | 2016-10-12 |
EP3110444B1 (fr) | 2018-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39294A1 (fr) | Polythérapie contre le cancer | |
MX2019001900A (es) | Forma cristalina de (s)-7-(1-acriloilpiperidin-4-il)-2-(4-fenoxife nil)-4,5,6,7-tetra-hidropirazolo[1,5-a]pirimidin-3-carboxamida, preparacion y usos de la misma. | |
MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
TN2015000174A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
PH12015500758A1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
EA201790995A1 (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ | |
SG10201803331PA (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
MD20150035A2 (ro) | Inhibitori de tirozinkinaza Bruton | |
BR112015010663A8 (pt) | formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo | |
MX2013010795A (es) | 1,3 oxazinas como inhibidores de beta-secretasa 1 (bace 1) y/o la beta-secretasa 2 (beta 2). | |
WO2013169864A3 (fr) | Tétrahydro[1,8]naphtyridine-sulfonamide et composés apparentés pour utilisation en tant qu'agonistes de rorγ et dans le traitement d'une maladie | |
AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
EA201690998A1 (ru) | НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ | |
MX337614B (es) | Tratamiento de lupus nefritis usando laquinimod. | |
MX2017012411A (es) | Co-cristales de un inhibidor de tirosina cinasa de bruton. | |
BR112018070017A2 (pt) | métodos de tratamento de cânceres pediátricos | |
SG10201901242PA (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
EA201492097A1 (ru) | 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1 | |
EA202190281A1 (ru) | Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диаза-спиро[4,5]декана | |
MA39447B1 (fr) | Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
MA39448B1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
WO2018033941A3 (fr) | Compositions pharmaceutiques à base d'ibrutinib | |
UA109359C2 (xx) | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном |